「药前沿」一年的靶向治疗,翻不过的山,迈不过的坎( 三 )


9.CHABON J J,SIMMONS A D,LOVEJOY A F,et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients[J]. Nat Commun,2016,7(1):118-125.
10.王春光. 肺癌分子靶向药物的作用机制及其耐药机制的研究进展[J]. 现代药物与临床, 2019, 34(01):273-279.
11.张文秋, 李永琦, 吴荻. Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors非小细胞肺癌EGFR-TKIs耐药——小细胞肺癌转化的研究进展[J]. 中国肺癌杂志, 020(10):720-726.
12.YochumZA, CadesJ, WangH, et al.Targeting the EMT transcription factor TWIST1 overcomes